Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AbbVie is conducting a Phase 3 study titled A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy. The study aims to assess the safety and effectiveness of upadacitinib in treating moderate to severe hidradenitis suppurativa (HS) in patients who have not responded to anti-TNF therapy. This research is significant as it could offer a new treatment option for HS, a painful inflammatory skin condition.
The intervention being tested is upadacitinib, an oral tablet already approved for several inflammatory conditions. It is being evaluated for its potential to treat HS by reducing disease activity and managing adverse events.
The study is interventional, with participants randomly assigned to receive either upadacitinib or a placebo in a parallel model. The trial is quadruple-masked, meaning neither the participants, care providers, investigators, nor outcomes assessors know who receives the actual drug. The primary purpose is treatment.
The study began on June 21, 2023, with a primary completion date yet to be announced. The last update was submitted on August 6, 2025. These dates are crucial for tracking the study’s progress and anticipated results.
Market implications of this study could be significant for AbbVie, potentially boosting its stock performance if upadacitinib proves effective for HS. This could enhance investor sentiment, especially in the context of competition within the pharmaceutical industry for innovative treatments for inflammatory conditions.
The study is ongoing, with further details available on the ClinicalTrials portal.